DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.56%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$362M
AUM Growth
+$362M
(+2.7%)
Cap. Flow
-$9.38M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
55.78%
Holding
86
New
3
Increased
22
Reduced
21
Closed
10
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$2.11M |
| 2 |
Compass Therapeutics
CMPX
|
$1.37M |
| 3 |
Inogen
INGN
|
$1.04M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$975K |
| 5 |
Day One Biopharmaceuticals
DAWN
|
$961K |
Top Sells
| 1 |
Merus
MRUS
|
$3.31M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$3.05M |
| 3 |
TSVT
2seventy bio
TSVT
|
$2.12M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$1.93M |
Sector Composition
| 1 | Healthcare | 85.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $34.5M | 9.51% | 415,505 +11,000 | +3% | +$912K |
|
2
Stereotaxis
STXS
$261M
| $29M | 8.01% | 13,680,554 | – | – |
|
3
Revolution Medicines
RVMD
$7.1B
| $24.9M | 6.88% | 677,176 +21,000 | +3% | +$773K |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $21.6M | 5.97% | 168,763 +16,500 | +11% | +$2.11M |
|
|
5
Merus
MRUS
$4.98B
| $21M | 5.79% | 398,804 -63,000 | -14% | -$3.31M |
|
6
AtriCure
ATRC
$1.84B
| $19.4M | 5.36% | 592,273 | – | – |
|
7
Cytokinetics
CYTK
$4.23B
| $13.2M | 3.63% | 398,100 | – | – |
|
8
IDEAYA Biosciences
IDYA
$2.15B
| $13M | 3.59% | 619,090 +29,760 | +5% | +$626K |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $13M | 3.58% | 102,500 | – | – |
|
10
Ascendis Pharma
ASND
$11.8B
| $12.5M | 3.46% | 72,677 -7,721 | -10% | -$1.33M |
|
11
Xenon Pharmaceuticals
XENE
$2.98B
| $9.01M | 2.49% | 287,939 +14,200 | +5% | +$444K |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $8.88M | 2.45% | 70,615 -1,000 | -1% | -$126K |
|
13
Axogen
AXGN
$743M
| $8.05M | 2.22% | 741,782 +61,000 | +9% | +$662K |
|
|
14
KalVista Pharmaceuticals
KALV
$678M
| $6.58M | 1.82% | 581,757 -170,602 | -23% | -$1.93M |
|
15
DexCom
DXCM
$29.5B
| $5.72M | 1.58% | 65,552 | – | – |
|
|
16
Day One Biopharmaceuticals
DAWN
$769M
| $5.71M | 1.58% | 879,163 +147,800 | +20% | +$961K |
|
17
Stoke Therapeutics
STOK
$1.08B
| $5.7M | 1.57% | 501,972 +57,974 | +13% | +$658K |
|
18
Tandem Diabetes Care
TNDM
$845M
| $5.48M | 1.51% | 294,208 | – | – |
|
19
Arcus Biosciences
RCUS
$1.13B
| $5.11M | 1.41% | 627,626 +2,500 | +0.4% | +$20.4K |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.09M | 1.41% | 543,602 -900 | -0.2% | -$8.43K |
|
21
Mineralys Therapeutics
MLYS
$1.03B
| $5.03M | 1.39% | 371,523 +62,323 | +20% | +$843K |
|
|
22
UroGen Pharma
URGN
$900M
| $4.79M | 1.32% | 349,515 -143,000 | -29% | -$1.96M |
|
|
23
Inogen
INGN
$216M
| $4.26M | 1.18% | 605,625 +147,560 | +32% | +$1.04M |
|
24
Galapagos
GLPG
$2.07B
| $3.64M | 1.01% | 130,175 | – | – |
|
25
Biohaven
BHVN
$1.63B
| $3.32M | 0.92% | 235,235 +15,000 | +7% | +$212K |
|